Literature DB >> 21827043

Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.

Dinora F González-Esquivel1, Nelly Castro, Jesús Ramírez-Bermúdez, Verónica Custodio, Susana Rojas-Tomé, Rafael Castro-Román, Helgi Jung-Cook.   

Abstract

The aim of the present study was to determine the prescribing practice for clozapine (CAS 5786-21-0) as well as the plasma levels of clozapine and its main metabolite norclozapine (CAS 6104-71-8) in Mexican patients. A prospective study was performed in 69 in and out psychotic patients taking clozapine. Blood samples were taken at steady state. Plasma concentrations of clozapine and norclozapine were determined by HPLC. The results showed that the mean daily dose administered was 250 mg/d. Plasma levels showed a large interindividual variability. Mean plasma levels were 411.3 +/- 328.12 ng/mL, for clozapine and 172.0 +/- 129.9 ng/mL for norclozapine. When data were compared with those reported in other populations, it was found that although the dose was lower than that reported in Caucasians, the plasma levels were similar. As a result, the predictive models for the estimation of clozapine concentration in Caucasians were not appropriate for application in Mexican patients. The findings suggest ethnic differences in the ratio dose/plasma levels of clozapine in Mexican patients. Further studies are required to expand the observations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827043     DOI: 10.1055/s-0031-1296207

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  A quantitative system pharmacology computer model for cognitive deficits in schizophrenia.

Authors:  H Geerts; P Roberts; A Spiros
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-03

2.  Steady-State Clozapine and Norclozapine Pharmacokinetics in Maori and European Patients.

Authors:  David B Menkes; Paul Glue; Christopher Gale; Frederic Lam; Cheung-Tak Hung; Noelyn Hung
Journal:  EBioMedicine       Date:  2017-12-13       Impact factor: 8.143

3.  Integrative Genomic-Epigenomic Analysis of Clozapine-Treated Patients with Refractory Psychosis.

Authors:  Yerye Gibrán Mayén-Lobo; José Jaime Martínez-Magaña; Blanca Estela Pérez-Aldana; Alberto Ortega-Vázquez; Alma Delia Genis-Mendoza; David José Dávila-Ortiz de Montellano; Ernesto Soto-Reyes; Humberto Nicolini; Marisol López-López; Nancy Monroy-Jaramillo
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.